MapLight Therapeutics Completes Enrollment for Two Phase 2 Trials, Reports Q1 Results
MPLT has more than doubled off its 52-week low of $12.24.
Summary
MapLight Therapeutics announced the completion of enrollment for its Phase 2 ZEPHYR and IRIS trials, with topline results anticipated by mid-August 2026, alongside Q1 2026 financial results and a reaffirmed cash runway through 2027.
Key Events · Product Development and Regulatory · MPLT
-
Phase 2 Enrollment Completed
Enrollment has been completed for ML-007C-MA's Phase 2 ZEPHYR trial in schizophrenia (307 participants) and ML-004's Phase 2 IRIS trial in autism spectrum disorder (161 participants).
-
Upcoming Topline Results
Topline results for both the ZEPHYR and IRIS trials are expected by mid-August 2026, representing significant near-term catalysts.
-
Q1 2026 Financials Reported
The company reported a net loss of $60.7 million for the first quarter of 2026, an increase from $22.3 million in Q1 2025, with R&D expenses rising to $53.7 million.
-
Cash Runway Extended Through 2027
MapLight Therapeutics ended Q1 2026 with $395.2 million in cash, cash equivalents, and investments, which is expected to fund operations through 2027.
Analysis · MPLT · Life Sciences
This 8-K highlights significant clinical progress for MapLight Therapeutics, with the completion of enrollment for two key Phase 2 trials (ZEPHYR for schizophrenia and IRIS for autism spectrum disorder). Topline results for both are expected by mid-August 2026, representing major near-term catalysts for the company. While the company reported an increased net loss for Q1 2026, its cash position of $395.2 million is expected to fund operations through 2027, providing a stable financial runway ahead of these critical data readouts.
At the time of this filing, MPLT was trading at $29.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $12.24 to $33.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.